The nation of Zimbabwe has rejected a major US healthcare agreement valued at $367m (£272m) over five years over Washington's request for sensitive information.
This move came to light after a government memo from December was disclosed, indicating that President Emmerson Mnangagwa deemed the deal was "lopsided".
An official representative later clarified that the United States was seeking health data for scientific study and commercial gain but refused to share the resulting advantages from future vaccines.
"We will now turn to the challenging and unfortunate process of ending our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had donated more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for further talks to secure a deal agreeable to all parties so the nation's vital HIV treatment initiative can be sustained.
Wider Implications
This rejection follows a similar case in neighbouring Kenya, where a high court blocked a related health funding agreement after legal challenges were filed about the safety of citizens' health data.
After resuming office last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
The agency had overseen aid for the American government, but Trump argued its expenditure was "inefficient" and his administration was seeking government-to-government agreements to boost transparency and accountability.
Based on reports, Sixteen African countries have to date agreed to these new health pacts, constituting more than $18.3bn of fresh investment.
Specifics of the Rejected Deal
The funds for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this collaboration might have yielded extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children presently on HIV treatment via US-supported initiatives," Tremont added.
However, government spokesperson Nick Mangwana said the proposed deal was "unequal".
"The proposal required Zimbabwe to share its biological resources and data for a long time, without any equivalent promise of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that provided information," his statement read.
"In essence, our country would supply the raw materials for scientific discovery without any assurance that the final treatments would be available to our population should a future health crisis emerge."
Sovereignty and Global Health
He also pointed out that the US's withdrawal from the global health body and its push of bilateral health agreements were disrupting frameworks previously established via the global health agency.
Mangwana cited its Pandemic Benefit-Sharing scheme created to manage potential global health emergencies.
"This system is designed to guarantee that when a nation provides its data, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised solely by those with the funds to create them."
These objections over the US deal "must not be interpreted as hostility towards the US," he added.
"We are open to further dialogue with our US partners on how subsequent collaboration might be designed in a manner that honours the independence and interests of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it understood the government's concerns, but urged that talks need to persist since much of the country's HIV programmes relied on foreign aid.
"In cases where specific concerns exist, such as those relating to information security or agreement terms, these can often be addressed via technical clarification and mutually agreed protections," it said.
The situation emphasises the complex challenges between receiving vital international aid and protecting a country's data in an increasingly interconnected world.